Related Experiment Video
Updated: Jul 1, 2026

Gastric Point of Care Ultrasound in Adults: Image Acquisition and Interpretation
Published on: September 22, 2023
[Prophylaxis of acute gastroduodenal lesions in critically ill patients]
Abstract:
There were 220 patients studied, of which 44 were considered "critical" according to pre-established factors. In all of them, intra-gastrical pH in serious forms was detected, establishing that 45% of the "non-critical" patients had a pH factor less than 4. In these 61 patients and in the 44 "critical" patients a gastric alkalinization was sought, using between 1.2 and 2.4 grams of cimetidina daily, to which alkalines were added when necessary. Nine percent of the critical patients (4 of 44) had H.D.A., while 11 of 33 (33%) of the critically ill from a previous series that had not been treated had pronounced gastro-intestinal bleeding lesions (p less than 0.01.) The potential difference of gastric mucous in critical patients was measured likewise, being significantly less (means = 17.37 +/- 1.13) than in the non-critical patients (means = 30.2 +/- 1.13) (p less than 0.005). The use of cimetidina as an inhibitor of gastric secretion in a dosage of 1.2 grams was effective in 73% of the non-critical patients and in only 29% of the critical patients. Despite an increase in the dosage up to 2.4 grams in 9% of the critical and 22% of the non-critical patients, it was necessary to add alkalines. This lack of response shows a correlation between the amount of risk factors (3 of 10 patients had 3 factors) and the existence of hepatitic insufficiency (5 out of 16 patients and 5 out of 26 of sepsis).
Related Concept Videos
Prevention of Further Absorption of Poison
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease

